<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In order to validate the results from the transcriptome analysis, the expression profiles of some candidate genes were estimated based on relative quantitation of mRNA transcripts and assayed by real‐time qPCR using a StepOnePlus Real‐Time PCR Systems (Applied Biosystems, Forest City, CA). We used the previously prepared cDNA samples of liver (
 <italic class="italic">n </italic>= 33) and brain (
 <italic class="italic">n </italic>= 18) tissues (see Section 
 <xref rid="eva12487-sec-0005" ref-type="sec" class="xref">2.3</xref>). Six DE genes from the brain transcriptome (NADH dehydrogenase subunit 5 (
 <italic class="italic">ND5</italic>); ATP synthase F0 subunit 6 (
 <italic class="italic">ATP6</italic>); somatolactin beta (
 <italic class="italic">smtlb</italic>); proopiomelanocortin a (
 <italic class="italic">pomca</italic>); thyroid‐stimulating hormone beta subunit a (
 <italic class="italic">tshba</italic>); lysine (K)‐specific demethylase 7Aa (
 <italic class="italic">kdma7aa</italic>)) and five DE genes from the liver transcriptome (apolipoprotein Ba (
 <italic class="italic">apoba</italic>); tetraspanin 13a (
 <italic class="italic">tspan13a</italic>); cat eye syndrome chromosome region, candidate 5 (
 <italic class="italic">cecr5</italic>); ATP‐binding cassette, subfamily A member 2 (
 <italic class="italic">abca2</italic>); transducin‐like enhancer of split 3a (
 <italic class="italic">tle3a</italic>)) were selected as candidate genes (see Section 
 <xref rid="eva12487-sec-0008" ref-type="sec" class="xref">3</xref>).
</p>
